Eli Lilly

Photo

Lilly Boosts Gene Therapy with Prevail Buy

Eli Lilly is to buy Prevail Therapeutics, a US biotech focused on developing adeno-associated viral vector 9 (AAV9) gene therapies to treat neurodegenerative diseases, in a deal that could be worth as much as $1.04 billion.

Photo

Lilly to Enter Gene Therapy with Precision BioSciences

Eli Lilly is wading into gene therapy, inking a deal with Precision BioSciences to develop in vivo gene therapies for three gene targets. The first target will be Duchenne muscular dystrophy, a disease caused by mutations in the dystrophin gene that prevent it from producing a protein of the same name. The other two have not been revealed.

101 more articles

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.